RECIST

RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve ("respond"), stay the same ("stable"), or worsen ("progression") during treatments. The main goal of RECIST is to provide a standardized method for assessing the response to treatments in solid tumors, for use in clinical trials.

History[edit | edit source]

The RECIST guidelines were first published in 2000 by a group of experts in the field of oncology. The guidelines were updated in 2009 to RECIST 1.1, which is the current version in use.

Methodology[edit | edit source]

The RECIST criteria are based on the sum of the longest diameter of target lesions. A minimum of two lesions are selected and measured at baseline. The sum of these measurements serves as a reference to further assess the tumor burden. The response to treatment is then categorized as follows:

Complete Response (CR): Disappearance of all target lesions
Partial Response (PR): At least a 30% decrease in the sum of the longest diameter of target lesions
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD
Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter of target lesions

Limitations[edit | edit source]

While RECIST has been widely adopted in clinical trials, it has several limitations. It does not account for changes in tumor density or the presence of new lesions. Furthermore, it is not applicable to all types of cancer, such as leukemia and lymphoma.

See Also[edit | edit source]

RECIST Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.